Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Other Non-Current Liabilities (2018 - 2024)

Pharma-Bio Serv filings provide 7 years of Other Non-Current Liabilities readings, the most recent being $660903.0 for Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $660903.0 in Q4 2024 year-over-year; TTM through Oct 2024 was $660903.0, a N/A change, with the full-year FY2024 number at $660903.0, changed N/A from a year prior.
  • Other Non-Current Liabilities hit $660903.0 in Q4 2024 for Pharma-Bio Serv, down from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.6 million in Q4 2022 to a low of $17950.0 in Q1 2020.
  • Median Other Non-Current Liabilities over the past 5 years was $17950.0 (2020), compared with a mean of $385000.7.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 96.77% in 2020 and later skyrocketed 9031.19% in 2022.
  • Pharma-Bio Serv's Other Non-Current Liabilities stood at $73389.0 in 2020, then plummeted by 75.54% to $17950.0 in 2021, then skyrocketed by 9031.19% to $1.6 million in 2022, then fell by 12.9% to $1.4 million in 2023, then plummeted by 53.7% to $660903.0 in 2024.
  • The last three reported values for Other Non-Current Liabilities were $660903.0 (Q4 2024), $1.4 million (Q3 2023), and $1.4 million (Q2 2023) per Business Quant data.